Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cencora, Inc.ABC · Entity 2994 | Executive Vice President | April 04, 2018 | April 05, 2018 |
| TANDEM DIABETES CARE INCTNDM · Entity 4682 | Director | May 20, 2026 | May 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cencora, Inc.
Report date April 04, 2018 · Filed April 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,989 |
Ending reported balance
After 2018-04-04 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2018-04-04 · Exercise / conversion · Acquired 1,200 · Balance 49,189 F1: The exercise of stock options and the sale of common stock reflected in this Form 4 were pursuant to a Rule 10b-5 trading plan dated August 21, 2017 governing stock options scheduled to expire on March 1, 2019 and November 13, 2020. Row 2 · 2018-04-04 · Sale · Disposed 1,200 · Balance 47,989 F1: The exercise of stock options and the sale of common stock reflected in this Form 4 were pursuant to a Rule 10b-5 trading plan dated August 21, 2017 governing stock options scheduled to expire on March 1, 2019 and November 13, 2020. Row 3 · 2018-04-04 · Exercise / conversion · Acquired 1,800 · Balance 49,789 F1: The exercise of stock options and the sale of common stock reflected in this Form 4 were pursuant to a Rule 10b-5 trading plan dated August 21, 2017 governing stock options scheduled to expire on March 1, 2019 and November 13, 2020. Row 4 · 2018-04-04 · Sale · Disposed 1,800 · Balance 47,989 F1: The exercise of stock options and the sale of common stock reflected in this Form 4 were pursuant to a Rule 10b-5 trading plan dated August 21, 2017 governing stock options scheduled to expire on March 1, 2019 and November 13, 2020. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.37 · Expires 2019-03-01 | Direct | 4,800 |
Reported balance
After 2018-04-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-04-04 · Exercise / conversion · Disposed 1,200 · Balance 4,800 F1: The exercise of stock options and the sale of common stock reflected in this Form 4 were pursuant to a Rule 10b-5 trading plan dated August 21, 2017 governing stock options scheduled to expire on March 1, 2019 and November 13, 2020. F2: Exercisable in four equal annual installments on 03/01/13, 03/01/14, 03/01/15 and 03/01/2016 |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.21 · Expires 2019-11-14 | Direct | 7,200 |
Reported balance
After 2018-04-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-04-04 · Exercise / conversion · Disposed 1,800 · Balance 7,200 F1: The exercise of stock options and the sale of common stock reflected in this Form 4 were pursuant to a Rule 10b-5 trading plan dated August 21, 2017 governing stock options scheduled to expire on March 1, 2019 and November 13, 2020. F3: Exercisable in four equal annual installments on 11/14/13, 11/14/14, 11/14/15 and 11/14/16 |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise of stock options and the sale of common stock reflected in this Form 4 were pursuant to a Rule 10b-5 trading plan dated August 21, 2017 governing stock options scheduled to expire on March 1, 2019 and November 13, 2020.
F2: Exercisable in four equal annual installments on 03/01/13, 03/01/14, 03/01/15 and 03/01/2016
F3: Exercisable in four equal annual installments on 11/14/13, 11/14/14, 11/14/15 and 11/14/16
TANDEM DIABETES CARE INC
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,836 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Exercise / conversion · Acquired 8,759 · Balance 29,836 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 10,220 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 10,220 · Balance 10,220 F1: Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F2: Such RSUs were granted to the Reporting Person on May 20, 2026, and will vest on the one-year anniversary thereof, subject to the terms of the 2023 Plan. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-21 · Exercise / conversion · Disposed 8,759 · Balance 0 F1: Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3: On May 21, 2025, the Reporting Person was granted 8,759 RSUs, all of which vested and converted into shares of the Issuers common stock on the one-year anniversary thereof in accordance with the 2023 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
F2: Such RSUs were granted to the Reporting Person on May 20, 2026, and will vest on the one-year anniversary thereof, subject to the terms of the 2023 Plan.
F3: On May 21, 2025, the Reporting Person was granted 8,759 RSUs, all of which vested and converted into shares of the Issuers common stock on the one-year anniversary thereof in accordance with the 2023 Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2017 Filed Mar 6, 2017 21:30 UTC | Cencora, Inc. ABC · Entity 2994 | Exercise / conversionCommon Stock | 45,000 | $36.37 | $1,636,650.00 |
DisclosureSEC source: 0001127602-17-010443 · form4.xml · nonDerivative · entry 1 Howell Peyton R · CIK 0001528056 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 22:55 UTC | Cencora, Inc. ABC · Entity 2994 | GrantCommon Stock | 8,760 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-16-067035 · form4.xml · nonDerivative · entry 3 Howell Peyton R · CIK 0001528056 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,135 F1 · price: Shares were received for no consideration upon the satisfaction of performance criteria underlying an award of performance share units. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 22:55 UTC | Cencora, Inc. ABC · Entity 2994 | Tax withholdingCommon Stock | 1,395 | $78.92 | $110,093.40 |
DisclosureSEC source: 0001127602-16-067035 · form4.xml · nonDerivative · entry 2 Howell Peyton R · CIK 0001528056 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,375 Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 22:55 UTC | Cencora, Inc. ABC · Entity 2994 | Tax withholdingCommon Stock | 4,185 | $80.78 | $338,064.30 |
DisclosureSEC source: 0001127602-16-067035 · form4.xml · nonDerivative · entry 1 Howell Peyton R · CIK 0001528056 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,770 Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 22:55 UTC | Cencora, Inc. ABC · Entity 2994 | GrantRestricted Stock Units · Derivative | 3,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-067035 · form4.xml · derivative · entry 5 Howell Peyton R · CIK 0001528056 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,968 Underlying: Common Stock · 3,968 shares Expires 2023-11-09 F3 · derivative.exercise_price: Annual grant of restricted stock units that vests 100% on the third anniversary of the date of grant for no consideration. F3 · derivative.exercise_date: Annual grant of restricted stock units that vests 100% on the third anniversary of the date of grant for no consideration. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 22:55 UTC | Cencora, Inc. ABC · Entity 2994 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 44,280 | $0.00 Strike: $75.61 | $0.00 |
DisclosureSEC source: 0001127602-16-067035 · form4.xml · derivative · entry 4 Howell Peyton R · CIK 0001528056 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,280 Underlying: Common Stock · 44,280 shares Expires 2023-11-09 F2 · derivative.exercise_date: Exercisable in four equal annual installments on 11/9/17, 11/9/18, 11/9/19 and 11/9/20 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.